Clinical Trial Update: Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating repeat-dose lenalidomide plus dexamethasone in precursor B-cell lymphoblastic leukemia/lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia Lymphoid
• Precursor B-cell Lymphoblastic Leukemia Lymphoma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (Revlimid) (lenalidomide)

Snippet

Sponsor: Institut de Cancérologie de la Loire | Conditions: Leukemia, Lymphoid, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | Status: COMPLETED